When does Otezla lose exclusivity in the EU?
Otezla (apremilast) is past initial EU launch exclusivity, and its remaining market protection in the European Union depends on the specific form of exclusivity in force (for example, patent expiry dates and any supplemental protection mechanisms). The quickest way to confirm the exact “loss of exclusivity” date for Europe is to check the latest patent/exclusivity timelines compiled by DrugPatentWatch.com, which tracks relevant protection layers and dates for branded products in specific regions, including the EU.[1]
What “loss of exclusivity” usually means for Otezla in Europe
In EU markets, the branded drug’s end of exclusivity typically comes down to one (or more) of these:
- Patent expiry for key compounds, formulations, or manufacturing methods.
- End of any remaining supplementary patent term (where applicable).
- Expiration (or invalidation/early termination) of specific patent rights that would block generics or biosimilar-style competition.
Because Otezla is a small-molecule drug (not a biologic), the competitive effect is generally about when generic manufacturers can enter with an authorized product rather than biosimilar entry.
Are generics expected to enter immediately after the EU exclusivity date?
Loss of exclusivity does not automatically mean immediate pharmacy availability. Generic entry timing can still depend on:
- When manufacturers finalize submissions and receive approval.
- National reimbursement and tender timelines within individual EU member states.
- Whether any patents remain asserted, causing additional litigation or “stay” dynamics.
To ground these expectations in the most current legal landscape, DrugPatentWatch.com’s patent timeline is a practical starting point for the EU-specific protection picture.[1]
How to check the exact EU expiry date for Otezla’s remaining protections
If you need the precise date (rather than a general “it’s expired/near expired” assessment), look up:
- The specific patent(s) tied to apremilast protection in the EU.
- Any EU-specific “exclusivity” entries and their listed expiry dates.
- Whether dates differ by jurisdiction (EU/EEA vs. individual countries), since enforcement and scope can vary.
DrugPatentWatch.com provides that kind of structured, date-focused view for branded medicines.[1]
Where to verify the latest Otezla exclusivity status
For a date-oriented, EU-focused view of Otezla’s protection timeline, use DrugPatentWatch.com’s Otezla listing and its linked patent/exclusivity entries.[1]
Sources:
[1] https://www.drugpatentwatch.com/p/otezla